Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma

Cancer

Volumn 85, Issue 1, 1999, Pages 100-103

  Costa, Luis A M ^a   Kopreski, Michael S ^b   Demers, Laurence M ^c   Chinchilli, Vernon M ^c   Santen, Richard J ^d   Harvey, Harold A ^c   Lipton, Allan ^c  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b PFIZER INC   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Aromatase inhibitor; Fadrozole hydrochloride (CGS 16949A); Hemostatic parameters; Lipids

Indexed keywords

ANTITHROMBIN; AROMATASE INHIBITOR; CHOLESTEROL; FADROZOLE; FIBRINOGEN; LIPID; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; DATA ANALYSIS; DOSE RESPONSE; ENZYME INHIBITION; FEMALE; HUMAN; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTITHROMBIN III; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CHOLESTEROL; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; FADROZOLE; FEMALE; FIBRINOGEN; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MIDDLE AGED; POSTMENOPAUSE; PROTEIN C; PROTEIN S; RISK FACTORS; TRIGLYCERIDES;

EID: 0032919446     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990101)85:1<100::AID-CNCR14>3.0.CO;2-5     Document Type: Article

References (11)

1. Santen RJ, Demers LM, Lynch J, Harvey HA, Lipton A, Mulagha M, et al. Specificity of low dose fadrozole hydrochloride (CGS 16949) as an aromatase inhibitor. J Clin Endocrinol Metab 1991;73:99-106.
2. Santen RJ, Demers LM, Adlercreutz H, Harvey HA, Santner S, Sanders S, et al. Inhibition of aromatase with CGS 16949 A in postmenopausal women. J Clin Endocrinol Metab 1989; 68:99-106.
3. Buzdar A, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, et al. Fadrozole HCL (CGS 16949 A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma. Cancer 1996;77:2503-13.
4. Love R, Wiebe AD, Newcomb P, Cameron L, Leventhal H, Jordan VC, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115:860-4.
5. McDonald CC, Stewart HJ, for the Scottish Breast Cancer Committee. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. BMJ 1991;303:435-7.
6. Love R, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.
7. Fisher B, Dignam Y, Wieand S, Wolmark N, Wickerham DL, and contributing investigators. Duration of tamoxifen therapy for primary breast cancer: 5 versus 10 years (NSABP B-14) [Abstract 118]. Proc ASCO 1996;15.
8. Gylling H, Mantyla E, Miettinen TA. Tamoxifen decreases serum cholesterol by inhibiting cholesterol synthesis. Artherosclerosis 1992;96:245-7.
9. Gylling H, Pyrhonen S, Mantyla E, Maenpaa H, Kangas L, Miettinen TA. Tamoxifen and toremifen lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer. J Clin Oncol 1995; 13:2900-5.
10. Jonat W, Howell A, Blonqvist P, Eirmann W, Fornander T, Tyrrell CJ, et al. A randomized trial of the new specific aromatase inhibitor arimidex versus megestrol acetate in the treatment of postmenopausal women with advanced breast cancer [Abstract 130]. Proc ASCO 1995;14.
11. Dombernowsky D, Smith I, Falkson G. Double blind randomized phase IIb/III trial of two doses of letrozole and megestrol acetate as second-line treatments for patients with breast cancer [Abstract 820]. Ann Oncol 1996;7.